Materials
| Name | Company | Catalog Number | Comments |
| C57BL/6J mice | Jackson Laboratory | 000664 | |
| B6.129S7-Rag1tm1Mom/J | Jackson Laboratory | 002216 | |
| Anti-CD3 (2C11) antibody | BD Biosciences | 553058 | |
| Anti-CD28 (37.51) antibody | BD Biosciences | 553295 | |
| Anti-CD3 (17A2) antibody | BioLegend | 100202 | |
| Anti-CD4 (GK1.5) antibody | BioLegend | 100417 | |
| Anti-CD8 (53-6.7) antibody | BioLegend | 100714 | |
| Anti-CD25 (3C7) antibody | BioLegend | 101912 | |
| Anti-CD44 (1M7) antibody | BioLegend | 103012 | |
| Anti-CD117 (2B8) antibody | BioLegend | 105812 | |
| Anti-TCR-β (H57597) antibody | BioLegend | 109220 | |
| Anti-IL-2 (JES6-5H4) antibody | BioLegend | 503810 | |
| Anti-IFN-γ (XMG1.2) antibody | BioLegend | 505822 | |
| DMEM | Invitrogen | ABCD1234 | |
| α-MEM | Invitrogen | A10490-01 | |
| FBS | Hyclone | SH3007.01 | |
| Brefeldin A | Sigma-Aldrich | B7651 | |
| Polybrene | Sigma-Aldrich | 107689 | |
| GeneJammer | Integrated Sciences | 204130 | |
| RNA kit | Qiagen | 74104 | |
| DNA kit | Qiagen | 69504 | |
| CD8 Isolation Kit | Miltenyi Biotec | 130-095-236 | |
| ACK lysis buffer | Lonza Inc. | 10-548E | |
| mFlt-3L | PeproTech Inc | 250-31L | |
| mIL-7 | PeproTech Inc | 217-17 | |
| Gelatin | Sigma-Aldrich | G9391 | |
| FITC-anti-OVA antibody | Rockland Immunochemicals | 200-4233 | |
| Permeabilization buffer | Biolegend | 421002 | |
| BSA | Sigma-Aldrich | A7906 | |
| Formaldehyde | Sigma-Aldrich | F8775 | |
| 0.4 μm filter | EMD Millipore | ||
| Moflo Cell Sorter | Dako | ||
| Calibur Flow Cytometer | BD Biosciences | ||
| LSR II Flow Cytometer | BD Biosciences | ||
| Mouse restrainer | Braintree Scientific, Inc. |
References
- Brenner, M. K., Heslop, H. E. Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 22, 251-257 (2010).
- Hataye, J., Moon, J. J., Khoruts, A., Reilly, C., Jenkins, M. K. Naive and memory CD4+ T cell survival controlled by clonal abundance. Science. 312, 114-116 (2006).
- Seki, Y. IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. J. Immunol. 178, 262-270 (2007).
- Stemberger, C. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity. 27, 985-997 (2007).
- Siewert, C. Experience-driven development: effector/memory-like alphaE+Foxp3+ regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells. J. Immunol. 180, 146-155 (2008).
- Wang, L. X., Plautz, G. E. Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure. J. Immunol. 184, 5612-5618 (2010).
- Hinrichs, C. S. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 117, 808-814 (2011).
- Alajez, N. M., Schmielau, J., Alter, M. D., Cascio, M., Finn, O. J. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 105, 4583-4589 (2005).
- Yang, L., Baltimore, D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 102, 4518-4523 (2005).
- Zhao, Y. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 67, 2425-2429 (2007).
- Boztug, K. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. Med, N. .E. ngl.J. . 363, 1918-1927 (2010).
- Peerani, R., Zandstra, P. W. Enabling stem cell therapies through synthetic stem cell-niche engineering. J. Clin. Invest. 120, 60-70 (2010).
- Mendez-Ferrer, S. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 466, 829-834 (2010).
- Daley, G. Q. Towards the generation of patient-specific pluripotent stem cells for combined gene and cell therapy of hematologic disorders. Hematology Am. Soc. Hematol. Educ. Program. , 17-22 (2007).
- Boitano, A. E. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 329, 1345-1348 (2010).
- Himburg, H. A. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat. Med. 16, 475-482 (2010).
- Tanigaki, K., Honjo, T. Regulation of lymphocyte development by Notch signaling. Nature immunology. 8, 451-456 (2007).
- Zhao, T., Zhang, Z. N., Rong, Z., Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature. 474, 212-215 (2011).
